Additional targeting of ERBB2 and NPYRs could enhance rational drug design and lead to the identification of novel modulators tailored for BC therapy, minimizing off-target effects while enhancing antitumor efficacy [36]. The gene discussed is ERBB2; the disease is breast cancer.